Ligand Pharmaceuticals Announces OmniAb Platform License Agreement With ABBA Therapeutics AG

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its OmniAb Platform license agreement with ABBA Therapeutics AG for antibody development. Under the agreement, ABBA is able to use the OmniRat®, OmniMouse® and OmniFlic® platforms and will be responsible for all costs related to the program. Read the press release.

ABBA is a Swiss biotechnology company that focuses on developing innovative immune-oncology therapies. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.